Cargando…

High dose melphalan, BCNU and etoposide with autologous bone marrow transplantation for Hodgkin's disease.

Thirty-eight patients with previously treated Hodgkin's disease were given high dose combination chemotherapy using melphalan and BCNU and autologous bone marrow transplantation. In 25 patients etoposide was added in conventional dosage. During the course of the study the dose of melphalan was...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zulian, G. B., Selby, P., Milan, S., Nandi, A., Gore, M., Forgeson, G., Perren, T. J., McElwain, T. J.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1989
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2247129/ https://www.ncbi.nlm.nih.gov/pubmed/2653400

Ejemplares similares

High dose BCNU chemotherapy with autologous bone marrow transplantation and full dose radiotherapy for grade IV astrocytoma.
por: Mbidde, E. K., et al.
Publicado: (1988)

Etoposide and adriamycin containing combination chemotherapy (HOPE-Bleo) for relapsed Hodgkin's disease.
por: Perren, T. J., et al.
Publicado: (1990)

High-dose melphalan with autologous marrow for treatment of advanced neuroblastoma.
por: Pritchard, J., et al.
Publicado: (1982)

Treatment of advanced malignant melanoma with high-dose melphalan and autologous bone marrow transplantation.
por: Cornbleet, M. A., et al.
Publicado: (1983)

Infused vincristine and adriamycin with high dose methylprednisolone (VAMP) in advanced previously treated multiple myeloma patients.
por: Forgeson, G. V., et al.
Publicado: (1988)

Enhanced anti-tumour activity of carmustine (BCNU) with tumour necrosis factor in vitro and in vivo.
por: Jones, A. L., et al.
Publicado: (1990)

Effect of high-dose melphalan on marrow and intestinal epithelium in mice pretreated with cyclophosphamide.
por: Millar, J. L., et al.
Publicado: (1978)

ChlVPP combination chemotherapy for Hodgkin's disease: long-term results.
por: Selby, P., et al.
Publicado: (1990)

Single high-dose etoposide and melphalan with non-cryopreserved autologous marrow rescue as primary therapy for relapsed, refractory and poor-prognosis Hodgkin's disease.
por: Seymour, L. K., et al.
Publicado: (1994)

Autologous transplantation in poor risk Hodgkin's disease using high dose melphalan/etoposide conditioning with non-cryopreserved marrow rescue. The Newcastle and Northern Region Lymphoma Group.
por: Taylor, P. R., et al.
Publicado: (1993)

Verapamil potentiation of melphalan cytotoxicity and cellular uptake in murine fibrosarcoma and bone marrow.
por: Robinson, B. A., et al.
Publicado: (1985)

Cyclophosphamide priming reduces intestinal damage in man following high dose melphalan chemotherapy.
por: Selby, P. J., et al.
Publicado: (1987)

Chemotherapy for malignant melanoma: combinations and high doses produce more responses without survival benefit.
por: Lakhani, S., et al.
Publicado: (1990)

PB2178: OUTCOMES OF REDUCED DOSE TEAM (THIOTEPA, ETOPOSIDE, CYTARABINE, MELPHALAN) PRIOR TO AUTOLOGOUS STEM CELL TRANSPLANTATION FOR HODGKIN AND NON-HODGKIN LYMPHOMA: A MONOCENTRIC EXPERIENCE
por: Di Folca, S., et al.
Publicado: (2022)

Comparable safety profile of BeEAM (bendamustine, etoposide, cytarabine, melphalan) and BEAM (carmustine, etoposide, cytarabine, melphalan) as conditioning before autologous haematopoietic cell transplantation
por: Frankiewicz, Andrzej, et al.
Publicado: (2018)

Marrow autotransplantation accelerates haematological recovery in patients with malignant melanoma treated with high-dose melphalan.
por: McElwain, T. J., et al.
Publicado: (1979)

The Use of Etoposide, Ara-Cytarabine, and Melphalan (EAM) Conditioning Chemotherapy in Autologous Stem Cell Transplantation (ASCT) for a Patient with Relapsed Hodgkin's Lymphoma
por: Pangarsa, Eko A., et al.
Publicado: (2021)

High-dose chemotherapy and autologous bone marrow transplant in relapsed Hodgkin's disease--a pragmatic prognostic index.
por: O'Brien, M. E., et al.
Publicado: (1996)

BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) Versus BEAM (Carmustine, Etoposide, Cytarabine, Melphalan) as Conditioning Regimen Before Autologous Haematopoietic Cell Transplantation: A Systematic Review and Meta-Analysis
por: Wu, Ran, et al.
Publicado: (2023)

Rapid VAC high dose melphalan regimen, a novel chemotherapy approach in childhood soft tissue sarcomas.
por: Pinkerton, C. R., et al.
Publicado: (1991)

Effects of verapamil and alcohol on blood flow, melphalan uptake and cytotoxicity, in murine fibrosarcomas and human melanoma xenografts.
por: Robinson, B. A., et al.
Publicado: (1986)

Epidermal growth factor (hEGF) has no effect on murine intestine epithelial damage and regeneration after melphalan.
por: Robinson, B. A., et al.
Publicado: (1985)

Repeat administration of high dose melphalan in relapsed myeloma.
por: Mansi, J. L., et al.
Publicado: (1993)

Hodgkin's Disease in Children
por: Smith, I. E., et al.
Publicado: (1977)

Postchemotherapy staging laparotomy in Hodgkin's disease.
por: Barr, L. C., et al.
Publicado: (1982)

Bendamustine, etoposide, and dexamethasone to mobilize peripheral blood hematopoietic stem cells for autologous transplantation in non-Hodgkin lymphoma
por: Greenbaum, Adam M., et al.
Publicado: (2018)

The results of radiotherapy for Hodgkins' disease.
por: Peckham, M. J., et al.
Publicado: (1975)

BCNU (Bis-chloroethylnitrosourea, Carmustine) Toxicity Presented as a Large Pleural Effusion 60 Days Post Autologous Stem Cell Transplant for Non-Hodgkin Lymphoma
por: Dvorak, Shelby N, et al.
Publicado: (2019)

The treatment of metastatic germ-cell testicular tumours with bleomycin, etoposide and cis-platin (BEP).
por: Peckham, M. J., et al.
Publicado: (1983)

High dose chemotherapy and autologous bone marrow transplantation in refractory Hodgkin's disease.
por: Philip, T., et al.
Publicado: (1986)

Melphalan, Etoposide, and Carboplatin Megatherapy with Autologous Stem Cell Transplantation in Children with Relapsing or Therapy-Resistant Extracranial Germ-Cell Tumors—A Retrospective Analysis
por: Ussowicz, Marek, et al.
Publicado: (2020)

Melphalan dose intensity for autologous stem cell transplantation in multiple myeloma
por: Srour, Samer A., et al.
Publicado: (2021)

A combination of chlorambucil, vinblastine, procarbazine and prednisolone for treatment of Hodgkin's disease.
por: McElwain, T. J., et al.
Publicado: (1977)

Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma
por: Rodriguez, Tulio E., et al.
Publicado: (2016)

Single-Agent High-Dose Melphalan as Conditioning Regimen in Autologous Hematopoietic Stem Cell Transplantation for Hodgkin's Lymphoma: Safety, and Long-Term Efficacy
por: Al Hashmi, Hani, et al.
Publicado: (2018)

Busulfan, Melphalan, and Etoposide (BuME) Showed an Equivalent Effect to Busulfan, Cyclophosphamide, and Etoposide (BuCE) as Conditioning Therapy for Autologous Stem Cell Transplantation in Patients with Relapsed or High-Risk Non-Hodgkin’s Lymphoma: A Multicenter Randomized Phase II Study by the Consortium for Improving Survival of Lymphoma (CISL)
por: Kim, Kyoung Ha, et al.
Publicado: (2023)

Busulfan plus melphalan versus high-dose melphalan as conditioning regimens in autologous stem cell transplantation for newly diagnosed multiple myeloma
por: Byun, Ja Min, et al.
Publicado: (2018)

Z-BeEAM (Ibritumomab tiuxetan, Bendamustine, Etoposide, Cytarabine, Melphalan) before autologous stem cell transplantation is safe and efficient for refractory large B-cell lymphoma
por: Tardy, Magalie P., et al.
Publicado: (2015)

Five years' experience with ChlVPP: effective low-toxicity combination chemotherapy for Hodgkin's disease.
por: Dady, P. J., et al.
Publicado: (1982)

Effect of renal dysfunction in dogs on the disposition and marrow toxicity of melphalan.
por: Alberts, D. S., et al.
Publicado: (1981)

Cannot write session to /tmp/vufind_sessions/sess_ecfpso3vkqph2trb0sllhk6vpn